Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares traded up 2.1% during mid-day trading on Friday . The company traded as high as $162.60 and last traded at $160.99, with a volume of 191,683 shares traded. The stock had previously closed at $157.69.

A number of research firms have weighed in on ICPT. Robert W. Baird restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Sunday, May 8th. Morgan Stanley restated a “sell” rating on shares of Intercept Pharmaceuticals in a research note on Sunday, May 8th. BMO Capital Markets restated a “buy” rating and issued a $239.00 price target on shares of Intercept Pharmaceuticals in a research note on Tuesday, May 3rd. Cowen and Company restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Sunday, April 17th. Finally, FBR & Co restated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Sunday, April 17th. Five research analysts have rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $177.67.

The firm’s 50-day moving average is $154.37 and its 200 day moving average is $138.12. The company’s market capitalization is $4.03 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, topping analysts’ consensus estimates of ($3.69) by $0.55. During the same period in the prior year, the firm posted ($1.99) earnings per share. The company had revenue of $5.52 million for the quarter, compared to the consensus estimate of $1.72 million. The business’s revenue for the quarter was up 1140.4% on a year-over-year basis. Equities analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.39) earnings per share for the current fiscal year.

In other news, insider Lisa Bright sold 251 shares of the company’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $137.50, for a total value of $34,512.50. Following the completion of the transaction, the insider now directly owns 18,855 shares of the company’s stock, valued at $2,592,562.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mark Pruzanski sold 714 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total value of $103,608.54. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. BlackRock Advisors LLC raised its position in Intercept Pharmaceuticals by 5.4% in the fourth quarter. BlackRock Advisors LLC now owns 125,274 shares of the biopharmaceutical company’s stock valued at $18,710,000 after buying an additional 6,461 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock valued at $5,468,000 after buying an additional 578 shares in the last quarter. New York State Common Retirement Fund raised its position in Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock valued at $5,586,000 after buying an additional 800 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 109 shares in the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.